سعر Xarelto 15 mg 42 f.c. tab 2026
- المادة الفعالة: Rivaroxaban
- Bayer Healthcare
- عن طريق الفم
الفئة: مضاد للتخثر
دواعي استعمال Xarelto 15
- Reduction of risk of stroke and systemic embolism in nonvalvular atrial fibrillation (15 mg dose for CrCl 50 mL/min or less)الفئة: AdultsDailyMed (U.S. National Library of Medicine)
- Treatment of deep vein thrombosis and pulmonary embolism (initial 21 days)الفئة: AdultsDailyMed (U.S. National Library of Medicine)
- Reduction of risk of stroke and systemic embolism in nonvalvular atrial fibrillation (15 mg dose for CrCl 50 mL/min or less)Population: AdultsDailyMed (U.S. National Library of Medicine)
- Treatment of deep vein thrombosis and pulmonary embolism (initial 21 days)Population: AdultsDailyMed (U.S. National Library of Medicine)
معلومات الدواء
التفاصيل الكاملةالآثار الجانبيةSide effects
- The most common adverse reactions are bleeding complications.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
- The most common adverse reactions are bleeding complications.International label, same formulation · DailyMed (U.S. National Library of Medicine)
موانع الاستعمالContraindications
- Active pathological bleeding.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
- Severe hypersensitivity reaction to rivaroxaban (e.g. anaphylaxis).نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
- Lesion or condition at significant risk of major bleeding; concomitant treatment with any other anticoagulant except when switching; hepatic disease associated with coagulopathy (incl. Child-Pugh B and C cirrhosis); pregnancy and breast-feeding.نشرة دولية لنفس التركيبة · European Medicines Agency
- Active pathological bleeding.International label, same formulation · DailyMed (U.S. National Library of Medicine)
- Severe hypersensitivity reaction to rivaroxaban (e.g. anaphylaxis).International label, same formulation · DailyMed (U.S. National Library of Medicine)
- Lesion or condition at significant risk of major bleeding; concomitant treatment with any other anticoagulant except when switching; hepatic disease associated with coagulopathy (incl. Child-Pugh B and C cirrhosis); pregnancy and breast-feeding.International label, same formulation · European Medicines Agency
تحذيرات واحتياطاتWarnings & precautions
- Boxed warning: premature discontinuation increases the risk of thrombotic events; consider coverage with another anticoagulant.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
- Boxed warning: epidural or spinal haematomas, which may cause long-term or permanent paralysis, can occur with neuraxial anaesthesia or spinal puncture.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
- Increased risk of bleeding, including serious or fatal bleeding; risk increased with aspirin, P2Y12 inhibitors, other antithrombotics, fibrinolytics, NSAIDs, SSRIs and SNRIs.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
- Boxed warning: premature discontinuation increases the risk of thrombotic events; consider coverage with another anticoagulant.International label, same formulation · DailyMed (U.S. National Library of Medicine)
- Boxed warning: epidural or spinal haematomas, which may cause long-term or permanent paralysis, can occur with neuraxial anaesthesia or spinal puncture.International label, same formulation · DailyMed (U.S. National Library of Medicine)
- Increased risk of bleeding, including serious or fatal bleeding; risk increased with aspirin, P2Y12 inhibitors, other antithrombotics, fibrinolytics, NSAIDs, SSRIs and SNRIs.International label, same formulation · DailyMed (U.S. National Library of Medicine)
التداخلات الدوائيةDrug interactions
- Combined P-gp and strong CYP3A inhibitors (e.g. ketoconazole, ritonavir)Increase rivaroxaban exposure and bleeding risk; avoid concomitant use.DailyMed (U.S. National Library of Medicine)
- Combined P-gp and strong CYP3A inducers (e.g. carbamazepine, phenytoin, rifampin, St John's wort)Decrease rivaroxaban exposure and may increase thromboembolic risk; avoid concomitant use.DailyMed (U.S. National Library of Medicine)
- Anticoagulants, aspirin, clopidogrel and NSAIDsCoadministration may increase bleeding risk; avoid other anticoagulants unless benefit outweighs risk and evaluate promptly any signs of blood loss.DailyMed (U.S. National Library of Medicine)
- Combined P-gp and strong CYP3A inhibitors (e.g. ketoconazole, ritonavir)Increase rivaroxaban exposure and bleeding risk; avoid concomitant use.DailyMed (U.S. National Library of Medicine)
- Combined P-gp and strong CYP3A inducers (e.g. carbamazepine, phenytoin, rifampin, St John's wort)Decrease rivaroxaban exposure and may increase thromboembolic risk; avoid concomitant use.DailyMed (U.S. National Library of Medicine)
- Anticoagulants, aspirin, clopidogrel and NSAIDsCoadministration may increase bleeding risk; avoid other anticoagulants unless benefit outweighs risk and evaluate promptly any signs of blood loss.DailyMed (U.S. National Library of Medicine)
الحمل والرضاعةPregnancy & breastfeeding
- Limited data are insufficient to inform drug-associated developmental risk; use with caution in pregnancy because of potential pregnancy-related haemorrhage and/or emergent delivery.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
- Contraindicated during pregnancy because of potential reproductive toxicity, intrinsic bleeding risk and placental passage; women of child-bearing potential should avoid becoming pregnant during treatment.نشرة دولية لنفس التركيبة · European Medicines Agency
- Rivaroxaban has been detected in human milk; insufficient data on effects on the breastfed child; weigh benefits of breastfeeding against maternal need.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
- Limited data are insufficient to inform drug-associated developmental risk; use with caution in pregnancy because of potential pregnancy-related haemorrhage and/or emergent delivery.International label, same formulation · DailyMed (U.S. National Library of Medicine)
- Contraindicated during pregnancy because of potential reproductive toxicity, intrinsic bleeding risk and placental passage; women of child-bearing potential should avoid becoming pregnant during treatment.International label, same formulation · European Medicines Agency
- Rivaroxaban has been detected in human milk; insufficient data on effects on the breastfed child; weigh benefits of breastfeeding against maternal need.International label, same formulation · DailyMed (U.S. National Library of Medicine)
تابع أسعار الأدوية أول بأول
بننشر كل يوم أسعار أدوية اتغيرت والبدائل الأرخص
المثائل (8)
كل المثائل والبدائلنفس المادة الفعالة والتركيز. اسأل الصيدلي قبل الاستبدال.
| الدواء | السعر | الفرق عن الأصلي |
|---|---|---|
| ثروموكسيبان 15مجم 10 اقراصThromoxiban 15 mg 10 tabsMedizen Pharmaceutical Industries · 15 mgالأرخص | السعر130ج.م13ج.م للوحدة | الفرق عن الأصليأرخص 1,631ج.م (92.6%) |
| اندوريفابان 15 مجم 20 قرصAndorivaban 15 mg 20 tabletsAl Andalous Pharmaceutical Industries · أقراص · 15 mg | السعر260ج.م13ج.م للوحدة | الفرق عن الأصليأرخص 1,501ج.م (85.2%) |
| اورجوركسابان 15مجم 20 قرصOrgoroxabanOrganopharma · أقراص مغلفة · 15 mg | السعر342ج.م17.1ج.م للوحدة | الفرق عن الأصليأرخص 1,419ج.م (80.6%) |
| ريباتوكسابان 15مجم 30 قرصRepatoxaban 15 mg 30 tabsEva Pharma · 15 mg | السعر360ج.م12ج.م للوحدة | الفرق عن الأصليأرخص 1,401ج.م (79.6%) |
| فاكساتو 15مجم 30 قرصVaxato 15 mg 30 tabsLiptis · أقراص مغلفة · 15 mg | السعر390ج.م13ج.م للوحدة | الفرق عن الأصليأرخص 1,371ج.م (77.9%) |
تاريخ السعر
تغيّر السعر الرسمي: من 1,344 إلى 1,761 ج.م، 2 أسعار مسجلة
| التاريخ | السعر (ج.م) |
|---|---|
| سعر سابق بدون تاريخ | 1,344 |
| 1,761 |
| التاريخ | من | إلى | التغيير |
|---|---|---|---|
| 1,344ج.م | 1,761ج.م | زيادة 31% |
أدوية ذات صلة
نفس المادة الفعالة بتركيز آخر
منتجات أخرى من Bayer Healthcare
المصادر
- السعر: قوائم أسعار الأدوية المنشورة في مصر.
- DailyMed (U.S. National Library of Medicine)
- European Medicines Agency
تعليقات
لا توجد تعليقات بعد. كن أول من يشارك تجربته مع هذا الدواء.
أضف تعليقًا